Differential uptake of tritiated digoxin in benign and malignant central nervous system neoplasms.
The purpose of this study was to measure uptake of tritiated digoxin by neoplastic tissues known to have differential contents of sodium-potassium adenosine triphosphatase (Na + K + ATPase), the presumed receptor for digoxin. Tumor samples were removed at the time of craniotomy in seven patients with meningiomas (Group 1) and seven patients with more malignant central nervous system tumors (Group 2) (three astrocytomas, three glioblastomas, one meduloblastoma). Patients with meningiomas were found to have a significantly higher digoxin uptake (21.8 +/- 7.3 ng/gm tumor versus 5.7 +/- 5.2 ng/gm tumor; (p less than 0.01) and a significantly greater tissue/serum ratio (13.9 +/- 11.7 versus 3.26 +/- 3.7, p less than 0.0). This study provides the first demonstration of increased uptake of digoxin by noncardiac pathologic tissues. The results are most likely due to differences in the number of digoxin receptor sites.
D000251:Adenosine Triphosphatases / Q000378:metabolism; D001254:Astrocytoma / Q000378:metabolism; D001932:Brain Neoplasms / Q000201:enzymology / Q000378:metabolism*; D004077:Digoxin / Q000378:metabolism*; D005260:Female; D005910:Glioma / Q000378:metabolism; D006801:Humans; D008297:Male; D008579:Meningioma / Q000378:metabolism; D008875:Middle Aged; D011188:Potassium / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D014316:Tritium
D014316:Tritium; D004077:Digoxin; D012964:Sodium; D000251:Adenosine Triphosphatases; D011188:Potassium